WATERS CORPORATION

2025 Historical Reported Revenue Breakdown — By Division

Supplemental Financial Information

Period	Analytical Sciences Division (ASD)	Biosciences Division (WBD)	Advanced Diagnostics Division (ADx)	Materials Sciences Division (MSD)
First Quarter 2025				
1Q25 Owned Period (Feb 9–)	—	$217	$268 (DS only)	—
1Q25 Full Quarter (Pro Forma)	$534	$352	$440 (DS) + $54 (CBU) = $494	$74
Second Quarter 2025				
2Q25	$626	$358	$425 (DS) + $63 (CBU) = $488	$82
Third Quarter 2025				
3Q25	$650	$387	$498 (DS) + $64 (CBU) = $562	$87
Fourth Quarter 2025				
4Q25	$731	$327	$439 (DS) + $93 (CBU) = $532	$108
FY 2025 (Calendar Year)	**$2,541**	**$1,424**	**$1,802 (DS) + $273 (CBU) = $2,075**	**$352**

Notes

(1) All figures are in millions of U.S. dollars (USD).

(2) The Analytical Sciences Division (ASD) reflects the former Waters Division, excluding the Clinical Business Unit (CBU), which is now reported within the Advanced Diagnostics Division (ADx). Prior period figures have been recast to reflect the current divisional reporting structure.

(3) The Biosciences Division (WBD) reflects the former BD Biosciences business.

(4) The Advanced Diagnostics Division (ADx) comprises the former BD Diagnostic Solutions business (DS) and the Clinical Business Unit (CBU) previously reported within the Waters Division. DS and CBU baseline figures are presented separately within ADx for comparability.

(5) The 1Q25 Owned Period represents estimated revenue from February 9, 2025 through the end of the quarter, reflecting the comparable prior-year period following the close of the acquisition of the Biosciences and Diagnostic Solutions businesses from Becton, Dickinson & Co on February 9, 2025. Please see the GAAP to Non-GAAP reconciliation in our May 5, 2026 earnings press release and presentation.

(6) Revenue figures for the Biosciences Division and the Diagnostic Solutions business within the Advanced Diagnostics Division for full quarterly periods in 2025 are derived from Becton, Dickinson and Company's (BDX) publicly available filings and financial disclosures.

(7) The 1Q25 Full Quarter (Pro Forma) figures for WBD and ADx represent the estimated full-quarter revenue for comparability purposes and are provided for investor modeling convenience.

(8) The Materials Sciences Division (MSD) reflects the TA Instruments business, which was formerly reported as a standalone segment.

(9) This supplemental schedule is provided for informational and investor modeling purposes only. It does not constitute a restatement of previously reported financial results. All figures are unaudited. Please refer to the "Safe Harbor" language included in Waters' First Quarter 2026 Earnings Press Release for important risk factors and cautionary statements.